Sunitinib, a highly selective multitargeted receptor TKI, can radiosensitize hypoxic ESCC cells and promote apoptosis in ESCC cells by inhibiting HIF-1α and VEGF upregulation but does not alter their cell cycle distribution [115]. This evidence concerns the gene VEGFA and esophageal squamous cell carcinoma.